Literature DB >> 23680234

A high throughput method for enrichment of natural killer cells and lymphocytes and assessment of in vitro cytotoxicity.

Edward C So1, Michelle A Sallin, Xiaoyu Zhang, Siaw L Chan, Lepakshi Sahni, Dan H Schulze, Eduardo Davila, Scott E Strome, Ajay Jain.   

Abstract

In vitro assessment of lymphocyte and natural killer (NK) cell cytotoxicity typically employs density gradient centrifugation and magnetic cell separation to isolate effector cells, and chromium release to assess cytotoxicity. In order to improve the rapidity and scalability of in vitro cytotoxicity assessment, we evaluated the efficacy of a protocol utilizing tetrameric antibody complexes and SepMate™ isolation tubes to negatively select NK cells (TACs/Sep), and calcein-AM release to measure cytotoxicity. We compared the efficiency and accuracy of this protocol to a conventional approach employing density gradient centrifugation and magnetically labeled antibodies (DG/MACS) to isolate NK cells and chromium release to measure cytotoxicity. The TACs/Sep method significantly decreased the time required for NK cell isolation (1h vs. 4h), but resulted in higher red blood cell contamination. NK cell activation marker expression (including CD94, NKG2D, NKp30, NKp46, DNAM-1, 2B4, KIR2DL1/S1, KIR2DL2/L3, intracellular granzyme B, and perforin) was similar when comparing NK cells isolated by the TACs/Sep or DG/MACS methods, but the TACs/Sep method induced higher expression of CD16. In vitro cytotoxicity against HT29 colon cancer and K562 leukemia cells was not affected by the isolation method. Lastly, by combining the TACs/Sep NK cell isolation method with calcein-acetoxymethyl diacetylester (calcein-AM) release, the time required to assess in vitro cytotoxicity was reduced by 33% (4h) compared to protocols employing DG/MACS and chromium release. Altogether, these results provide the foundation for the development of a rapid, high throughput functional assay, and make it practical for the multiplexing of downstream applications, such as flow cytometric analysis and enzyme-linked immunosorbent assays (ELISAs). Published by Elsevier B.V.

Entities:  

Keywords:  ADCC; Calcein; Chromium release; Magnetic cell separation; Rapid high-throughput; Tetrameric antibody complexes

Mesh:

Year:  2013        PMID: 23680234     DOI: 10.1016/j.jim.2013.05.001

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients.

Authors:  P Schlegel; T Feuchtinger; C Nitschke-Gérard; U J Eva Seidel; A-M Lang; C Kyzirakos; H-M Teltschik; M Ebinger; M Schumm; E Koscielniak; R Handgretinger; P Lang
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

2.  Cell-based assays using calcein acetoxymethyl ester show variation in fluorescence with treatment conditions.

Authors:  Fayth L Miles; Jill E Lynch; Robert A Sikes
Journal:  J Biol Methods       Date:  2015

3.  A HER2 bispecific antibody can be efficiently expressed in Escherichia coli with potent cytotoxicity.

Authors:  Limin Lin; Li Li; Changhua Zhou; Jing Li; Jiayu Liu; Rui Shu; Bin Dong; Qing Li; Zhong Wang
Journal:  Oncol Lett       Date:  2018-05-11       Impact factor: 2.967

4.  Functional and pharmacological analysis of cardiomyocytes differentiated from human peripheral blood mononuclear-derived pluripotent stem cells.

Authors:  Michael Riedel; Chuanchau J Jou; Shuping Lai; Robert L Lux; Alonso P Moreno; Kenneth W Spitzer; Elizabeth Christians; Martin Tristani-Firouzi; Ivor J Benjamin
Journal:  Stem Cell Reports       Date:  2014-05-29       Impact factor: 7.765

5.  BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells.

Authors:  Jieyu Xing; Limin Lin; Jing Li; Jiayu Liu; Changhua Zhou; Haitao Pan; Rui Shu; Bin Dong; Donglin Cao; Qing Li; Zhong Wang
Journal:  Transl Oncol       Date:  2017-08-07       Impact factor: 4.243

6.  O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.

Authors:  Bruno Permanne; Astrid Sand; Solenne Ousson; Maud Nény; Jennifer Hantson; Ryan Schubert; Christoph Wiessner; Anna Quattropani; Dirk Beher
Journal:  ACS Chem Neurosci       Date:  2022-03-31       Impact factor: 5.780

7.  A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells.

Authors:  Aifen Li; Jieyu Xing; Li Li; Changhua Zhou; Bin Dong; Ping He; Qing Li; Zhong Wang
Journal:  AMB Express       Date:  2016-04-26       Impact factor: 3.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.